Mexico City, 24 July 2018: Mundipharma has expanded its ophthalmology portfolio in Latin America by agreeing a new commercial partnership with NTC – an Italian pharmaceutical company with deep experience in research and development – for exclusive rights to license and distribute a range of ophthalmic medicines across the region.
This builds on the existing agreement between the two organizations for the Middle East and Africa region signed in December 2017.
NTC’s portfolio was developed to address unmet medical needs in the treatment of several ophthalmic diseases, including blepharitis, dry eye, allergies and glaucoma.
“The addition of the NTC medicines complements Mundipharma’s current ophthalmology portfolio in Latin America,” said Mundipharma CEO, Raman Singh. “It’s another bold and important step in our efforts to establish market leadership in the region backed by a strong and diversified portfolio of medicines. This is an excellent addition to our existing glaucoma portfolio, given these medicines help treat many of the associated conditions that glaucoma patients experience.
“We are delighted to extend our relationship with NTC. As its strategic partner in Latin America, Mundipharma can now leverage its world class development and clinical programs to improve clinical outcomes in ophthalmology in the region,” added Mr Singh. “This is a great result for patients, who will benefit from improved access to more high quality medicines.
NTC President and CEO, Riccardo Carbucicchio, said “The strong partnership with Mundipharma enables NTC to further strengthen its internationalization strategy”. “With this agreement with Mundipharma in Latin America we are taking a significant step entering NTC into new markets.”
“The ability to bring our innovation onto the international stage via partnerships with global leading players like Mundipharma is a great achievement for NTC. We are excited to help bring medicines of high therapeutic value to patients in these geographies and to contribute to better clinical outcomes in ophthalmology”.
As well as licensing and distribution rights, Mundipharma will also continue to benefit from NTC’s commitment to research and development in ophthalmology.
NTC operates an international ophthalmology research and development program called Italian Innovation. Through the program, it engages with a large number of opinion leaders and clinical centres to focus on developing novel therapeutic solutions, with rich clinical insights, to offer the scientific community tangible therapeutic evidence to unleash better and more affordable therapeutic treatments for patients.
About NTC Srl
NTC is a pharmaceutical company headquartered in Milan – Italy, with distributors and partners in over 100 countries in the world, engaged in research, development, registration and commercialization of drugs, medical devices and food supplements in ophthalmology, but also in other therapeutic areas like paediatrics and gastro-metabolism. NTC offers to its partners, currently above 200 companies, innovative pharmaceutical products with high quality standards. For more details, please see NTC’s website (http://www.ntcpharma.com).
Mundipharma is a network of independent associated companies which are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, the Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma is a prime example of an organisation that consistently delivers high quality medicines while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.